image

SEC Filing Details

We are focused on the rapid design and development of new medicines based on breakthroughs in cancer research.
SEC Filing Details

Document Details

Form
Filing Date
February 17, 2022
Document Date
February 15, 2022
Form Description
Statement of changes in beneficial ownership of securities
Filing Group
3,4,5
Company
Prelude Therapeutics
Issuer
PRELUDE THERAPEUTICS INC
Filer
Chardonnet Laurent